Business Context and Reporting Period
This Form 8-K is a current report filed by TNF Pharmaceuticals, Inc. (Ticker: TNFA) on September 20, 2024. The filing addresses corporate governance matters specifically regarding the scheduling of the 2024 Annual Meeting of Stockholders and the deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.08 (Shareholder Director Nominations) and contains no financial performance data.
Material Changes
The primary material change disclosed is the rescheduling of the 2024 Annual Meeting of Stockholders. The meeting date has been changed by more than 30 days from the anniversary of the 2023 Annual Meeting. Consequently, the Board has established a new record date and specific deadlines for shareholder actions.
Guidance, Outlook, and Management Commentary
- Meeting Date: The 2024 Annual Meeting is scheduled for Monday, November 25, 2024.
- Record Date: The record date for determining stockholders entitled to vote is the close of business on October 18, 2024.
- Proposal Deadlines:
- Rule 14a-8 Proposals: Must be received by the Secretary on or before October 3, 2024.
- Bylaw Proposals/Nominations: Written notice must be received by the Secretary no later than October 3, 2024.
- Universal Proxy Rules: Notice for soliciting proxies for director nominees other than the Company's nominees must be provided by October 3, 2024.
- Location: The specific time and location will be detailed in the definitive proxy statement to be filed with the SEC.
Key Facts for Investor Verification
- Verify the October 3, 2024 deadline for submitting any shareholder proposals or director nominations to ensure eligibility for the November 25, 2024 meeting.
- Confirm the October 18, 2024 record date to determine voting eligibility.
- Monitor the upcoming definitive proxy statement for the specific time and location of the Annual Meeting.
- Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial data.